Liraglutide safety, tolerability, pharmacokinetics, and pharmacodynamics assessed in obese children aged 7-11 years
A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years
Abstract
A Phase 1 trial aims to evaluate liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in obese children aged 7-11.